Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta‐analyses of randomized controlled trials
British Journal of Clinical Pharmacology2016Vol. 83(5), pp. 1108–1117
Citations Over TimeTop 12% of 2016 papers
Lucas Miyake Okumura, Fernanda d’Athayde Rodrigues, Maria Angélica Pires Ferreira, Leila Beltrami Moreira
Abstract
Triple therapy decreased CIV risk, without increasing the occurrence of febrile neutropenia. However, this review could not address which subpopulations would most benefit from using this strategy. Future studies should focus on assessing risk factors for nausea and vomiting, as many patients did not achieve a complete antiemetic response.
Related Papers
- → Aprepitant for antiemesis after laparoscopic gynaecological surgery(2015)30 cited
- → The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting(2015)17 cited
- → Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial(2023)5 cited
- Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy(2009)
- → Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting(2013)